1613619-97-8

Upstream product

• 1613621-87-6 (S)-4-(2-bromo-4-carboxyphenyl)-6-methyl-2-thioxo-1-(3-trifluoromethylphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester (+)-cinchonine salt 
• 1613621-87-6 C₁₉H₂₂N₂O*C₂₁H₁₆BrF₃N₂O₄S 
• 89891-69-0 3-bromo-4-formyl benzonitrile 
• 1426800-29-4 5-(2-bromo-4-cyanophenyl)-7-methyl-3-oxo-8-[3-(trifluoromethyl)phenyl]-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylic acid methyl ester 
• 1613621-58-1 4-(2-bromo-4-cyanophenyl)-2-(N'-ethoxycarbonyl-hydrazino)-6-methyl-1-(3-trifluoromethylphenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 1613621-57-0 4-(2-bromo-4-cyanophenyl)-2-hydrazino-6-methyl-1-(3-trifluoromethylphenyl)-1,4-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 1613621-56-9 4-(2-bromo-4-cyanophenyl)-6-methyl-2-thioxo-1-(3-trifluoromethylphenyl)-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester 
• 105-45-3 acetoacetic acid methyl ester 
• 1736-70-5 3-trifluoromethylphenylthiourea 
• 1613621-89-8 (S)-4-(2-bromo-4-cyanophenyl)-6-methyl-2-thioxo-1-(3-trifluoromethylphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester 
• 1613621-88-7 (S)-4-(2-bromo-4-carbamoyl-phenyl)-6-methyl-2-thioxo-1-(3-trifluoromethyl-phenyl)-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester 
• 1613621-86-5 (S)-4-(2-Bromo-4-carboxy-phenyl)-6-methyl-2-thioxo-1-(3-trifluoromethyl-phenyl)-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester 
• 1613621-85-4 4-(2-bromo-4-carboxyphenyl)-6-methyl-2-thioxo-1-(3-trifluoromethylphenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester 
• 91760-66-6 3-bromo-4-formyl-benzoic acid 

Downstream Products

• 1613620-00-0 (3-{5-cyano-2-[(R)-6-methoxycarbonyl-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-propyl)-trimethyl-ammonium benzenesulfonate 

Relevant academic research and scientific papers

NOVEL COMPOUNDS

This invention relates to heterocyclic compounds, which are pyrimidinone derivatives having human neutrophil elastase inhibitory properties, and their use in therapy.

NOVEL COMPOUNDS

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated.